Margaret Moline

TL;DR: Donepezil had no effect on the primary endpoint, the V-ADAS-cog score in CADASIL patients with cognitive impairment, and improvements were noted on several measures of executive function, but the clinical relevance of these findings is not clear.

TL;DR: Effectiveness and tolerability of increasing donepezil from 10 to 23 mg/d in patients with moderate to severe AD was determined, and the LSM Delta in SIB score and CIBIC+ treatment effect at end point were greater withdonepezil 23mg/d than 10 mg/D in patientsWith more advanced AD compared with less impaired patients.

TL;DR: Performance was satisfactory at the scale level, but most ADAS-cog components were too easy for many patients in this sample and did not reflect the expected depth and range of cognitive performance.

TL;DR: Evidence is presented suggesting that donepezil can improve cognition, executive function, and global status in PDD.

TL;DR: The differential treatment response of VaD patients by hippocampal size suggests that hippocampal imaging warrants further investigation for understanding VaD, and donepezil was relatively well tolerated.